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tients. Patients receiving midazolam had higher mortal-
ity rates (31.7%) compared to patients on lorazepam
(29.2%). However, these results were not confirmed
when controlling for disease severity and other factors.
Multivariate regression analysis revealed that type of sed-
ative/analgesic drug treatment and whether the hospital
had a care plan were not associated with shorter ICU and
total hospital stays when controlling for patient demo-
graphics and disease severity. In fact, patients admitted to
hospitals with care plans had longer total hospital stays.
More severe patients had shorter total hospital stays,
probably due to higher mortality. Higher mortality was
associated with older patients and higher disease severity.
CONCLUSION: There is much discussion about treat-
ment guidelines and use of care plans to improve quality
of care and reduce hospitalization costs. In this study, the
type of sedation and analgesia treatment in mechanically
ventilated ICU patients and whether the patient had a
care plan did not influence days in ICU or mortality.
Whether following treatment guidelines and care plans
reduces total costs, needs further evaluation.
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OBJECTIVE: The objective of this study was to deter-
mine the frequency and cost of prescription switches for
90-day vs. 30-day outpatient prescriptions dispensed by a
VA pharmacy and to develop a model to determine the
prescription fill policy with the lowest total costs.
METHODS: VA outpatient prescription records for one
year for simvastatin and lovastatin (30 or 90-days) were
analyzed to determine the frequency, quantity and cost of
medication wasted due to medication switches. The
quantity wasted was defined as the difference between
the quantity dispensed and the quantity of drug used be-
fore changing to a new drug or dosage. Differences in dis-
pensing costs for a given time-period were also included.
Sensitivity analyses were conducted for quantity wasted,
drug costs, and dispensing costs. RESULTS: A total of
16,990 prescriptions were analyzed. The quantity and
costs of medication wasted were higher for 90-day pre-
scriptions than for 30-day prescriptions. However, aver-
age costs to the VA pharmacy were $2.45 higher per pre-
scription for the 30-day supply because of additional
dispensing costs for the 30-day fill. The model and sensi-
tivity analyses show that a 90-day supply policy results in
lower total pharmacy costs under several scenarios. Only
in the case of high drug costs was the 30-day policy fa-
vorable to the 90-day policy in terms of total costs.
CONCLUSION: Prescriptions given in a 90-day supply
resulted in lower total costs. The projected cost savings of
having a 90-day versus a 30-day policy would hold true
for prescriptions with similar drug costs and similar rates
of wastage that result from changes that physicians make
to patients’ prescriptions. In addition, the model provides
a flexible framework for pharmacy administrators to as-
sess refill policies in terms of excess or unnecessary cost
for different classes of drugs, given patient and/or physi-
cian behavior.
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OBJECTIVE: To understand how pharmacy spending
varies across the VA Medical Centers in the United States.
Pharmacy costs continue to rise. From 1990 to 1994
pharmacy expenditures were reported to be 6% of the to-
tal Veteran’s Health Association (VHA) budget. In 1995
and 1996 it was 7%. In 1997 it was 8% and in 1998 it
was 9%. Then in 1999 it went to 11%. Future projections
are for a continued increase in budget spending. METH-
ODS: Ratios of yearly Pharmacy to Medical Center ex-
penditures were compared. These ratios were ranked and
compared with geographical location. The years of 1997
and 1998 were studied. RESULTS: The majority of the
highest ratios were located in the Midwest, Soutwest, and
Southern regions of the United States. CONCLUSIONS:
Financial ratios can demonstrate variations in expendi-
tures and identify areas that may require further inquiry.
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BACKGROUND: A new drug is approved for use if its
effectiveness has been demonstrated. Recently decision-
makers in a number of countries have begun to account
for both the effectiveness and cost-effectiveness of new
drugs. However, cost-effectiveness evidence lags behind
the effectiveness data. OBJECTIVE: To explore the time-
liness of delivering cost-effectiveness information about
new drugs with established effectiveness and significant
financial impact. METHODS: New drugs were identi-
fied, based on guidance documents and reports published
by the National Institute for Clinical Excellence of En-
gland and Wales, and the following data were collected:
dates of publication of first effectiveness and cost-effec-
tiveness evidence, methodology of the cost-effectiveness
analysis, funding of the research, etc. RESULTS: Guid-
ance documents for the following new drugs/drug groups
have been published by NICE by the end of 2000: tax-
